In a prostate cancer xenograft model a reduction in tumor weight was observed after implantation of tumor-reactive CD8+ T cells which were TGF-β insensitive due to introduction of a dominant-negative TGF-β type II receptor vector [103]. This evidence concerns the gene TGFB1 and prostate cancer.